Business Context and Reporting Period
This Form 8-K filing by Ultragenyx Pharmaceutical Inc. reports a material definitive agreement entered into on February 26, 2019. The filing details an underwritten public offering of common stock that closed on March 1, 2019.
Key Financial Metrics
- Shares Sold: 5,072,464 shares of common stock at a public offering price of $60.00 per share.
- Option Exercise: Underwriters exercised a 30-day option in full on February 27, 2019, to purchase an additional 760,869 shares.
- Net Proceeds: The Company estimates net proceeds of approximately $330.4 million after deducting underwriters' discounts, commissions, and estimated offering expenses.
- Underwriters: J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, and Cowen and Company, LLC.
Material Changes
The primary material change is the significant increase in equity capital through the public offering. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a current report regarding a specific transaction rather than a periodic financial statement.
Outlook, Risks, and Contingencies
The Company agreed to indemnify the Underwriters against certain liabilities, including those under the Securities Act of 1933, or to contribute to payments required by the Underwriters. The offering was conducted under a prospectus supplement filed pursuant to an automatically effective shelf registration statement on Form S-3. No specific forward-looking guidance or risk factors beyond standard underwriting indemnities are detailed in this specific filing text.
Investor Verification Checklist
- Verify the final closing date and total share count including the full exercise of the 760,869 share option.
- Confirm the actual net proceeds received versus the estimated $330.4 million after all expenses.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific indemnification clauses and lock-up provisions.
- Check subsequent filings for the intended use of the raised capital.